Fig. 1. STL treatment causes dose-dependent suppression of FOXM1 protein levels in cancer cell lines of different etiology.
a Structural formula of STL. b-e Various cell lines representing human prostate (b), HGSOC (c), colorectal (d), or NSCLC (e) cancer were treated with increasing concentrations of STL for 24 h. Total protein samples obtained from treated cells were analyzed for FOXM1 protein levels via immunoblotting, β-actin was used as internal loading control.